

b1
3. (Amended) A polypeptide having an amino acid sequence comprising an amino acid sequence having at least 90% identity to the amino acid sequence of the metalloproteinase domain or the prodomain of SEQ ID NO 2.

b2
15. (Amended) A pharmaceutical composition for the treatment of arthritis, inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity and rejection, cachexia, allergy, cancer, tissue ulcerations, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joints implants, atherosclerosis, aortic aneurysm, congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neurodegenerative diseases, autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, infertility or diabetic shock comprising a therapeutically effective amount of a polypeptide of claim 3 in combination with a pharmaceutically acceptable carrier.

Kindly add the following claims:

- A3*
16. The polypeptide of claim 3 having an amino acid sequence comprising an amino acid sequence having at least 90% identity to the amino acid sequence of the metalloproteinase domain of SEQ ID NO 2.
 17. The polypeptide of claim 3 having an amino acid sequence comprising an amino acid sequence having at least 90% identity to the amino acid sequence of the prodomain of SEQ ID NO 2.
 18. The polypeptide of claim 3 comprising the amino acid sequence of SEQ ID NO: 2.
 19. The polypeptide of claim 3 comprising amino acids 289 to 478 of SEQ ID NO: 2.

20. The polypeptide of claim 3 comprising amino acids 19 to 287 of SEQ ID NO: 2.
21. The polypeptide of claim 3 having an amino acid sequence comprising an amino acid sequence having at least 95% identity to the amino acid sequence of the metalloproteinase domain.
22. The polypeptide of claim 3 having an amino acid sequence comprising an amino acid sequence having at least 95% identity to the amino acid sequence of the prodomain.
23. The polypeptide of claim 3 having an amino acid sequence comprising an amino acid sequence having at least 97% identity to the amino acid sequence of the metalloproteinase domain.
24. The polypeptide of claim 3 having an amino acid sequence comprising an amino acid sequence having at least 97% identity to the amino acid sequence of the prodomain.
b3
25. The polypeptide of claim 3 having an amino acid sequence comprising an amino acid sequence having at least 99% identity to the amino acid sequence of the metalloproteinase domain.
26. The polypeptide of claim 3 having an amino acid sequence comprising an amino acid sequence having at least 99% identity to the amino acid sequence of the prodomain.
27. The polypeptide of claim 22 having 5 to 10 amino acids substituted, deleted, or added, or combinations of such changes.
28. The polypeptide of claim 21 having 1 to 5 amino acids substituted, deleted, or added, or combinations of such changes.

- B3
C-1*
29. The polypeptide of claim 22 having 1 to 5 amino acids substituted, deleted, or added, or combinations of such changes.
 30. The polypeptide of claim 21 having 1 amino acid substituted, deleted, or added.
 31. The polypeptide of claim 22 having 1 amino acid substituted, deleted, or added.
 32. The polypeptide of claim 21 having 1 to 5 conservative amino acid substitutions.